AvalehtHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Viimane sulgemishind
25,85 €
Tänane vahemik
25,67 € - 25,67 €
Aasta vahemik
19,52 € - 36,69 €
Turuväärtus
3,58 mld USD
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 126,19 mln | 28,63% |
Puhastulu | −125,30 mln | −357,42% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −1,02 | −326,67% |
EBITDA | −121,67 mln | −339,34% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 520,91 mln | 8,30% |
Kogu vara | 955,15 mln | 7,16% |
Kõik kohustused | 459,74 mln | 7,87% |
Kogu omakapital | 495,40 mln | — |
Emiteeritud aktsiate arv | 124,20 mln | — |
Hinna ja väärtuse suhe P/B | 6,63 | — |
Varade tasuvus | −39,90% | — |
Kapitali tasuvus | −43,18% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −125,30 mln | −357,42% |
Põhitegevuse rahakäive | −92,38 mln | −191,68% |
Investeeringute raha | −268,94 mln | −645,70% |
Finantseerimise raha | 430,78 mln | 82 741,73% |
Raha ja raha ekvivalentide muutus | 69,49 mln | 203,27% |
Tasuta rahavoog | −91,82 mln | −262,49% |
Teave
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Tegevjuht
Asutatud
1. jaan 2004
Veebisait
Töötajate arv
525